Ondine Biomedical Stock Current Liabilities

OBI Stock   7.75  0.25  3.12%   
Ondine Biomedical fundamentals help investors to digest information that contributes to Ondine Biomedical's financial success or failures. It also enables traders to predict the movement of Ondine Stock. The fundamental analysis module provides a way to measure Ondine Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ondine Biomedical stock.
As of December 11, 2024, Total Current Liabilities is expected to decline to about 3.3 M. In addition to that, Non Current Liabilities Total is expected to decline to about 151.1 K.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Ondine Biomedical Company Current Liabilities Analysis

Ondine Biomedical's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition

Ondine Total Current Liabilities

Total Current Liabilities

3.32 Million

At present, Ondine Biomedical's Total Current Liabilities is projected to increase significantly based on the last few years of reporting.
In accordance with the recently published financial statements, Ondine Biomedical has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United Kingdom stocks is 100.0% higher than that of the company.

Did you try this?

Run Global Correlations Now

   

Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Ondine Fundamentals

About Ondine Biomedical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ondine Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ondine Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ondine Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Ondine Stock

Ondine Biomedical financial ratios help investors to determine whether Ondine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ondine with respect to the benefits of owning Ondine Biomedical security.